How to manage postmenopausal osteoporosis?

Acta Clinica Belgica

Volumn 66, Issue 6, 2011, Pages 443-447

  Body, J J ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bisphosphonate; Denosumab; Osteoporosis; Raloxifene; Strontium

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; LASOFOXIFENE; PARATHYROID HORMONE; PHYTOESTROGEN; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIETARY INTAKE; DIZZINESS; HEADACHE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERPARATHYROIDISM; ISCHEMIC HEART DISEASE; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; STROKE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES; VITAMIN D;

EID: 84255192160     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.66.6.2062612     Document Type: Conference Paper

References (26)

1. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149: 2445-2448. (Pubitemid 19283200)
2. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7: 407-413. (Pubitemid 27443065)
3. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006; 368: 973-974. (Pubitemid 44353676)
4. Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010; 21: 1657-1680.
5. Body JJ, Bergmann P, Boonen S, et al. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int 2011; 22: 2769-2788.
6. Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008; 42: 246-249.
7. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92: 1415-1423. (Pubitemid 46556419)
8. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 2006; 17: 313-316. (Pubitemid 43053597)
9. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761. (Pubitemid 39654569)
10. Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2011, in press.
11. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 1997; 277: 1159-1164. (Pubitemid 27157636)
12. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517-523. (Pubitemid 34925645)
13. Watts NB, Brown JP, Cline G. Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1 year compared with historical placebo. J Clin Densitom 2010; 13: 228-236.
14. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-1846. (Pubitemid 43877933)
15. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009; 20: 291-297.
16. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. (Pubitemid 46698462)
17. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809. (Pubitemid 350044800)
18. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24: 1095-1102.
19. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441. (Pubitemid 32402100)
20. Kumar S, Matheny CJ, Hoffman SJ, et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010; 46: 534-542.
21. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468. (Pubitemid 38133766)
22. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822. (Pubitemid 40686329)
23. Body JJ. Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther, in press.
24. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
25. Canalis E. New treatment modalities in osteoporosis. Endocr Pract 2010; 16: 855-863.
26. Li X, Warmington KS, NIu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010; 25: 247-256.3